Sprint Bioscience: Additional support for the DISA program and the TREX1 potential - Redeye

The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the effect of immuno-oncology therapy, radiation therapy, and chemotherapy in the treatment of cancer. Our take is that Sprint Bioscience is increasingly well-placed to attract a DISA TREX1 inhibitor program partner.

Länk till analysen i sin helhet: https://www.redeye.se/research/995434/sprint-bioscience-additional-support-for-the-disa-program-and-the-trex1-potential?utm_source=finwire&utm_medium=RSS